Neupogen Market, By Indication (Chemotherapy-induced neutropenia in non-myeloid malignancies, Neutropenia in acute myeloid leukemia (AmL) patients post induction or consolidation chemotherapy, Neutropenia post-myeloablative chemotherapy followed by bone m

The global Neupogen market, while initially experiencing growth, is now facing a decline due to several factors. Neupogen (filgrastim) is a recombinant human granulocyte colony-stimulating factor (G-CSF) that stimulates the production of neutrophils, which are essential for fighting infections. It is primarily used to prevent and treat neutropenia, a condition often induced by chemotherapy or radiation therapy. However, despite its effectiveness, the market is now shrinking. The market is declining due to several challenges, including the high cost of Neupogen, which limits its accessibility, particularly in low- and middle-income countries. Furthermore, the availability of biosimilars and alternative treatment options like pegfilgrastim and lenograstim have increased competition and reduced Neupogen's market share.

Market Dynamics

The market for Neupogen, while still benefiting from growing awareness about the importance of supportive care in cancer treatment, particularly in preventing febrile neutropenia and its complications, is experiencing slower growth. Despite ongoing research and development efforts to expand Neupogen’s indications and introduce innovative delivery systems, such as sustained-release formulations and transdermal patches, these advancements have not been sufficient to counterbalance the overall decline in market demand. While the aging population and rising cancer incidence continue to sustain some demand, cost-related factors and increasing competition are significantly impacting the market's growth trajectory. As a result, the Neupogen market is currently on a downward trend.

Key Features of the Study

• This report provides an in-depth analysis of the global Neupogen market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global Neupogen market based on the following parameters: company highlights, product portfolio, key highlights, financial performance, and strategies
• Key company covered as a part of this study includes Amgen Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global Neupogen market report caters to various stakeholders in this industry, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Neupogen market

• Indication Insights (Revenue, USD Mn, 2020 - 2032)
• Chemotherapy-induced neutropenia in non-myeloid malignancies
• Neutropenia in acute myeloid leukemia (AmL) patients post-induction or consolidation chemotherapy
• Neutropenia post-myeloablative chemotherapy followed by bone marrow transplantation (BMT)
• Mobilization of autologous hematopoietic progenitor cells for leukapheresis
• Chronic neutropenia (congenital, cyclic, idiopathic)
• Hematopoietic Syndrome of Acute Radiation Syndrome (H-ARS)
• Dose Strength Insights (Revenue, USD Mn, 2020 - 2032)
• 300mcg/1mL
• 480mcg/1.6mL
• 300MGC/0.5mL
• 480mcg/0.8mL
• Packaging Insights (Revenue, USD Mn, 2020 - 2032)
• Single-use vials
• Prefilled syringes
• Patient Age Group Insights (Revenue, USD Mn, 2020 - 2032)
• Pediatric
• Adult
• Geriatric
• Sales Channel Insights (Revenue, USD Mn, 2020 - 2032)
• Online
• Offline
• End User Insights (Revenue, USD Mn, 2020 - 2032)
• Hospitals
• Oncology Clinics
• Ambulatory Surgical Centers
• Others (Academic & Research Institutions, etc.)
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Amgen Inc.